Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Regulated Information...…
0,000€
-80,00%
Echtzeit-Aktienkurs Thrombogenics N.V.
Bid:
Ask:
Nachrichten zur Thrombogenics N.V. Aktie
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program
Leuven, BELGIUM, Boston, MA, US – August 11, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LL
Regulated Information...…
Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB
Total Potential Development and Commercial Milestones of $32M plus Royalties...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC
Leuven, BELGIUM, Boston, MA, US – June 15, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR) a…
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
Top-line Data Expected in Q4 2023...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
…
Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC
...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
…
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC
Leuven, BELGIUM, Boston, MA, US – April 27, 2023 – 7:00 pm CET – Oxurion NV (Euronext Brussels: OXUR) a…
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated Information...…
Oxurion Publishes 2022 Annual Report
Regulated Information...…
Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL
...…
Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes
Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular…
Oxurion Receives Transparency Notification from Negma Group
Oxurion Receives Transparency Notification from Negma Group...…
Oxurion Receives Transparency Notification from Negma Group
Oxurion Receives Transparency Notification from Negma Group...…
Funding Program between Oxurion and Negma Ends
Funding Program between Oxurion and Negma Ends...…
Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding
Oxurion Announces Subscription Agreement with AtlasProviding the Company with Up To €20 Million in Funding...…
Oxurion Receives Transparency Notifications from Negma Group
Oxurion Receives Transparency Notifications from Negma Group...…
Oxurion Receives Transparency Notifications from Negma Group
Oxurion Receives Transparency Notifications from Negma Group...…
Oxurion Receives Transparency Notifications from Negma Group
Oxurion Receives Transparency Notifications from Negma Group...…
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program...…
Oxurion Announces Second Amendment to Negma Funding Program
Oxurion Announces Second Amendment to Negma Funding Program...…
Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis
Trial Continues with Top-line Data Anticipated 2H 2023...…
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 80 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of…
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 322 convertible bonds in Oxurion resulting in a EUR 805,000 capital increase. This is part of…
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 312 convertible bonds in Oxurion resulting in a EUR 780,000 capital increase. This is part of…
Oxurion Further Improves THR-149 Patent Position
Secures Revocation of Patent for Peptide Inhibitor of Plasma Kallikrein (PKal) ...…
Oxurion Announces Interim Analysis for KALAHARI Trial
Interim Analysis for KALAHARI trial planned by Year-End 2022 with Full Top-Line Data Expected in Second half of 2023...…
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 56 convertible bonds in Oxurion resulting in a EUR 140,000 capital increase. This is part of…
Oxurion Receives Transparency Notifications Based on New Denominator
Leuven, BELGIUM, Boston, MA, US – November 17, 2022 – 8 AM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical…
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 130 convertible bonds in Oxurion resulting in a EUR 325,000 capital increase. This is part of…
Oxurion Receives Transparency Notification from Fidelity Management & Research Company LLC
Leuven, BELGIUM, Boston, MA, US – November 4, 2022 – 7 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical…
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of…
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1,450,000 capital increase. This is part of…
Oxurion To Participate in Upcoming Investor Conferences
Leuven, BELGIUM, Boston, MA, US – October 18, 2022 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a…